Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
W AulitzkyC Huber

Abstract

We tested the clinical efficacy of a biologically active dose (BAD) of interferon (IFN)-gamma for treatment of progressive renal cell carcinoma (RCC). Twenty-two RCC patients with disease progression subsequent to nephrectomy were entered on a phase II clinical trial. During an initial dose-finding phase, biochemical responses to repeated once-weekly subcutaneous injections of 10, 100, or 500 micrograms of recombinant IFN-gamma were tested in 16 patients. Results indicated that 100 micrograms IFN-gamma applied once weekly was biologically active with induction of serum beta 2-microglobulin and neopterin. Such a dose induced a nearly maximum response of both markers lasting more than 4 days. This dose was also associated with minimal side effects. A dose of 100 micrograms IFN-gamma given once weekly was, therefore, subsequently given weekly for long-term treatment. During a median time of therapy of 10 months (range, 2 to 32 months) two complete (CR; 20+, 20+ months) and four partial tumor responses (PR; 6+, 7+, 8+, 24+ months) were seen (30% CR plus PR; 95% confidence limits, 12% to 54%) among 20 patients evaluable for response. Patients with refractory disease had significantly lower IFN-gamma-induced increments of serum beta ...Continue Reading

Citations

Jul 9, 1991·International Journal of Cancer. Journal International Du Cancer·A J BeniersJ A Schalken
Feb 1, 1995·Cancer Immunology, Immunotherapy : CII·F OttoR Engelhardt
Jun 14, 2000·Cancer Biotherapy & Radiopharmaceuticals·M DeLimaJ Ellerhorst
Apr 11, 2013·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Siddharth Balachandran, Gregory P Adams
Feb 28, 2018·Cell Proliferation·Jing ShenChi H Cho
Aug 1, 1992·The Journal of Urology·C MrstikF Stögermayer
May 8, 2001·Cancer Investigation·R D PastoreD M Nanus
Jul 1, 1994·Cancer Immunology, Immunotherapy : CII·E WeidmannT L Whiteside
Sep 13, 2018·Journal of Cellular Biochemistry·Gaopei MengNa Xiao
Mar 9, 2019·Current Oncology Reports·Bryden Considine, Michael E Hurwitz
Nov 11, 1991·International Journal of Cancer. Journal International Du Cancer·H J GrussF Herrmann
Dec 1, 1994·Journal of Interferon Research·A M LiberatiB Palumbo
Nov 1, 1996·Cancer Control : Journal of the Moffitt Cancer Center·G P Haas, G G Hillman
Oct 24, 2008·American Journal of Physiology. Renal Physiology·Kazuyoshi NakamuraManabu Kubokawa
Jan 30, 2019·International Journal of Biomaterials·Hari Sharan Adhikari, Paras Nath Yadav
Oct 1, 1990·Japanese Journal of Cancer Research : Gann·H Shimizu, T Fujimoto
Sep 1, 1994·The Journal of Urology·J A EllerhorstC J Logothetis
Dec 15, 1994·International Journal of Cancer. Journal International Du Cancer·H BernhardK H Meyer zum Büschenfelde
Jan 1, 1996·International Journal of Urology : Official Journal of the Japanese Urological Association·M H Sokoloff, A Belldegrun
May 10, 2013·Molecular Cancer Therapeutics·Roshan J ThapaSiddharth Balachandran
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward M MessingUNKNOWN Eastern Cooperative Oncology Group/Intergroup trial
Sep 29, 2000·Urologic Oncology·J Vuky, R J Motzer
Jan 1, 1992·Clinical Immunology and Immunopathology·E C Borden
Jan 10, 2002·Journal of Pharmaceutical Sciences·Husam M Younes, Brian G Amsden

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.